» Articles » PMID: 29950691

The Role of PANSS Symptoms and Adverse Events in Explaining the Effects of Paliperidone on Social Functioning: a Causal Mediation Analysis Approach

Overview
Journal NPJ Schizophr
Date 2018 Jun 29
PMID 29950691
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

To date, no study has evaluated the joint role of symptoms and adverse events as mediators of the effect of second-generation antipsychotics on patients' social functioning. We used recently developed methods for mediation analysis with multiple mediators to clarify the interplay of adverse events and symptoms in explaining the effects of paliperidone (R code for implementing the mediation analysis for multiple mediators is provided). We used data from 490 participants in a 6-week randomized dose-response trial that assigned three fixed dosages of ER OROS paliperidone (3, 9, and 15 mg/day). The primary outcome was an individual's score on the social performance scale assessed after 6 weeks. The sum of Positive and Negative Syndrome Scale (PANSS), weight gain, and extrapyramidal symptoms measured via the Simpson-Angus Scale after 5 weeks were investigated as potential mediators and effect modifiers of treatment effects. Results from mediation analyses showed that the improvements in social functioning are partly explained by reduction in PANSS symptoms. Suggestive evidence that adverse events could play a role as mediators was found. In particular, weight gain displayed a non-linear relationship with social functioning, whereby beneficial effects observed at small levels of weight gain were reduced in the presence of excessive weight gain. In conclusion, we found that the short-term effects of paliperidone on social functioning were dependent on the successful reduction in PANSS symptoms and possibly the occurrence of excessive weight gain, thus suggesting future directions for treatment and interventions.

Citing Articles

Polybrominated diphenyl ethers and gestational weight gain: a multi-center prospective cohort study.

Wang Z, Williams P, Bellavia A, Wylie B, Kannan K, Bloom M BJOG. 2024; 131(11):1484-1494.

PMID: 38853304 PMC: 11483211. DOI: 10.1111/1471-0528.17860.


Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia.

Cochran J, Fang H, Gallo C, Peters-Strickland T, Lindenmayer J, Reuteman-Fowler J Patient Prefer Adherence. 2022; 16:1805-1817.

PMID: 35923658 PMC: 9342879. DOI: 10.2147/PPA.S362889.


Serum periostin among infants with severe bronchiolitis and risk of developing asthma: A prospective multicenter cohort study.

Nanishi M, Fujiogi M, Freishtat R, Hoptay C, Bauer C, Stevenson M Allergy. 2022; 77(7):2121-2130.

PMID: 35000210 PMC: 9247040. DOI: 10.1111/all.15216.


Maintenance treatment with antipsychotic drugs for schizophrenia.

Ceraso A, Lin J, Schneider-Thoma J, Siafis S, Tardy M, Komossa K Cochrane Database Syst Rev. 2020; 8:CD008016.

PMID: 32840872 PMC: 9702459. DOI: 10.1002/14651858.CD008016.pub3.


Overview and experience of the YODA Project with clinical trial data sharing after 5 years.

Ross J, Waldstreicher J, Bamford S, Berlin J, Childers K, Desai N Sci Data. 2018; 5:180268.

PMID: 30480665 PMC: 6257043. DOI: 10.1038/sdata.2018.268.

References
1.
Nasrallah H, Targum S, Tandon R, McCombs J, Ross R . Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005; 56(3):273-82. DOI: 10.1176/appi.ps.56.3.273. View

2.
Vittinghoff E, Sen S, McCulloch C . Sample size calculations for evaluating mediation. Stat Med. 2008; 28(4):541-57. DOI: 10.1002/sim.3491. View

3.
VanderWeele T, Vansteelandt S . Mediation Analysis with Multiple Mediators. Epidemiol Methods. 2015; 2(1):95-115. PMC: 4287269. DOI: 10.1515/em-2012-0010. View

4.
Martin E, Ongur D, Cohen B, Lewandowski K . Social functioning and age across affective and nonaffective psychoses. J Nerv Ment Dis. 2014; 203(1):37-42. PMC: 4290159. DOI: 10.1097/NMD.0000000000000232. View

5.
Burns T, Patrick D . Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand. 2007; 116(6):403-18. DOI: 10.1111/j.1600-0447.2007.01108.x. View